Levocarnitine Patent Expiration
Levocarnitine is Used for treating and preventing carnitine deficiency in end stage renal disease patients undergoing dialysis. It was first introduced by Leadiant Biosciences Inc
Levocarnitine Patents
Given below is the list of patents protecting Levocarnitine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Carnitor | US6335369 | Treating chronic uremic patients undergoing periodical dialysis |
Jan 18, 2021
(Expired) | Leadiant Biosci Inc |
| Carnitor | US6429230 | Treating chronic uremic patients undergoing periodical dialysis |
Jan 18, 2021
(Expired) | Leadiant Biosci Inc |
| Carnitor | US6696493 | Treating chronic uremic patients undergoing periodic dialysis |
Jan 18, 2021
(Expired) | Leadiant Biosci Inc |
Levocarnitine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levocarnitine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Children's Oncology Group | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |